Literature DB >> 30551012

Synaptic potentiation and rapid antidepressant response to ketamine in treatment-resistant major depression: A replication study.

Allison C Nugent1, Kathleen E Wills2, Jessica R Gilbert2, Carlos A Zarate2.   

Abstract

Preclinical and clinical evidence has demonstrated that ketamine has rapid antidepressant effects. Studies using pre-treatment with an AMPA inhibitor suggest that enhancing AMPA throughput is crucial to ketamine's effects, including increases in both basal and evoked gamma power. This study sought to replicate previous findings of increased gamma response to a somatosensory stimulus at 230 min and Day 1 in ketamine responders versus non-responders in 31 depressed subjects and 25 healthy controls. A significant difference in peak gamma power was seen in the depressed ketamine responders versus non-responders. These results implicate AMPA throughput in ketamine's mechanism of antidepressant action.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Depression; Ketamine; Magnetoencephalography (MEG)

Mesh:

Substances:

Year:  2018        PMID: 30551012      PMCID: PMC6410365          DOI: 10.1016/j.pscychresns.2018.09.001

Source DB:  PubMed          Journal:  Psychiatry Res Neuroimaging        ISSN: 0925-4927            Impact factor:   2.376


  6 in total

Review 1.  Synaptic AMPA receptor plasticity and behavior.

Authors:  Helmut W Kessels; Roberto Malinow
Journal:  Neuron       Date:  2009-02-12       Impact factor: 17.173

2.  Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression.

Authors:  Brian R Cornwell; Giacomo Salvadore; Maura Furey; Craig A Marquardt; Nancy E Brutsche; Christian Grillon; Carlos A Zarate
Journal:  Biol Psychiatry       Date:  2012-04-21       Impact factor: 13.382

3.  A new depression scale designed to be sensitive to change.

Authors:  S A Montgomery; M Asberg
Journal:  Br J Psychiatry       Date:  1979-04       Impact factor: 9.319

4.  The effects of AMPA blockade on the spectral profile of human early visual cortex recordings studied with non-invasive MEG.

Authors:  Suresh D Muthukumaraswamy; Bethany Routley; Wouter Droog; Krish D Singh; Khalid Hamandi
Journal:  Cortex       Date:  2016-03-31       Impact factor: 4.027

5.  NMDAR inhibition-independent antidepressant actions of ketamine metabolites.

Authors:  Panos Zanos; Ruin Moaddel; Patrick J Morris; Polymnia Georgiou; Jonathan Fischell; Greg I Elmer; Manickavasagom Alkondon; Peixiong Yuan; Heather J Pribut; Nagendra S Singh; Katina S S Dossou; Yuhong Fang; Xi-Ping Huang; Cheryl L Mayo; Irving W Wainer; Edson X Albuquerque; Scott M Thompson; Craig J Thomas; Carlos A Zarate; Todd D Gould
Journal:  Nature       Date:  2016-05-04       Impact factor: 49.962

6.  Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects.

Authors:  Allison C Nugent; Elizabeth D Ballard; Todd D Gould; Lawrence T Park; Ruin Moaddel; Nancy E Brutsche; Carlos A Zarate
Journal:  Mol Psychiatry       Date:  2018-02-27       Impact factor: 15.992

  6 in total
  15 in total

1.  Cost-Utility Analysis of Electroconvulsive Therapy and Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression in Ontario.

Authors:  Kyle P Fitzgibbon; Donna Plett; Brian C F Chan; Rebecca Hancock-Howard; Peter C Coyte; Daniel M Blumberger
Journal:  Can J Psychiatry       Date:  2019-12-05       Impact factor: 4.356

2.  Magnetoencephalography biomarkers of suicide attempt history and antidepressant response to ketamine in treatment-resistant major depression.

Authors:  Jessica R Gilbert; Jessica L Gerner; Courtney R Burton; Allison C Nugent; Carlos A Zarate; Elizabeth D Ballard
Journal:  J Affect Disord       Date:  2022-06-18       Impact factor: 6.533

Review 3.  Electrophysiological biomarkers of antidepressant response to ketamine in treatment-resistant depression: Gamma power and long-term potentiation.

Authors:  Jessica R Gilbert; Carlos A Zarate
Journal:  Pharmacol Biochem Behav       Date:  2020-01-17       Impact factor: 3.533

4.  Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression.

Authors:  Cristan A Farmer; Jessica R Gilbert; Ruin Moaddel; Jomy George; Lilian Adeojo; Jacqueline Lovett; Allison C Nugent; Bashkim Kadriu; Peixiong Yuan; Todd D Gould; Lawrence T Park; Carlos A Zarate
Journal:  Neuropsychopharmacology       Date:  2020-04-06       Impact factor: 7.853

Review 5.  Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants.

Authors:  Bashkim Kadriu; Maximillian Greenwald; Ioline D Henter; Jessica R Gilbert; Christoph Kraus; Lawrence T Park; Carlos A Zarate
Journal:  Int J Neuropsychopharmacol       Date:  2021-01-20       Impact factor: 5.176

6.  Fine-tuning neural excitation/inhibition for tailored ketamine use in treatment-resistant depression.

Authors:  Rosalyn J Moran; Jessica R Gilbert; Erik D Fagerholm; Robert Leech; Steven Williams; Carlos A Zarate
Journal:  Transl Psychiatry       Date:  2021-05-29       Impact factor: 6.222

Review 7.  Neurobiological biomarkers of response to ketamine.

Authors:  Bashkim Kadriu; Elizabeth D Ballard; Ioline D Henter; Stephen Murata; Nimesha Gerlus; Carlos A Zarate
Journal:  Adv Pharmacol       Date:  2020-06-18

8.  Ketamine Alters Electrophysiological Responses to Emotional Faces in Major Depressive Disorder.

Authors:  Nancy B Lundin; Linnea Sepe-Forrest; Jessica R Gilbert; Frederick W Carver; Maura L Furey; Carlos A Zarate; Allison C Nugent
Journal:  J Affect Disord       Date:  2020-10-07       Impact factor: 4.839

Review 9.  Biomarkers of ketamine's antidepressant effect: a clinical review of genetics, functional connectivity, and neurophysiology.

Authors:  Alexandra A Alario; Mark J Niciu
Journal:  Chronic Stress (Thousand Oaks)       Date:  2021-05-31

10.  Ketamine and Attentional Bias Toward Emotional Faces: Dynamic Causal Modeling of Magnetoencephalographic Connectivity in Treatment-Resistant Depression.

Authors:  Jessica R Gilbert; Christina S Galiano; Allison C Nugent; Carlos A Zarate
Journal:  Front Psychiatry       Date:  2021-06-18       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.